Becton, Dickinson and Company $BDX Shares Sold by Nuance Investments LLC

Key Points

• Nuance Investments LLC trimmed its Becton, Dickinson stake by 24.8% in the fourth quarter, selling 41,322 shares and leaving it with 125,213 shares worth about $24.3 million.
• Insider selling also occurred, with CEO Thomas E. Polen, Jr. selling 2,764 shares under a pre-arranged Rule 10b5-1 plan for about $404,511.
• BDX reported better-than-expected quarterly results, including EPS of $2.90 versus estimates of $2.77 and revenue of $4.71 billion, while also declaring a quarterly dividend of $1.05 per share.

Nuance Investments LLC cut its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 24.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 125,213 shares of the medical instruments supplier's stock after selling 41,322 shares during the period. Becton, Dickinson and Company accounts for about 2.7% of Nuance Investments LLC's portfolio, making the stock its 13th largest position. Nuance Investments LLC's holdings in Becton, Dickinson and Company were worth $24,300,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after acquiring an additional 4,223,149 shares during the period. State Street Corp lifted its stake in Becton, Dickinson and Company by 3.4% during the 3rd quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier's stock valued at $2,596,496,000 after acquiring an additional 459,219 shares during the period. First Eagle Investment Management LLC lifted its stake in Becton, Dickinson and Company by 16.5% during the 4th quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier's stock valued at $2,260,139,000 after acquiring an additional 1,651,592 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Becton, Dickinson and Company by 3.7% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 9,486,694 shares of the medical instruments supplier's stock valued at $1,841,083,000 after acquiring an additional 336,110 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier's stock valued at $1,331,165,000 after purchasing an additional 53,884 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of Becton, Dickinson and Company stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares of the company's stock, valued at $16,122,355.05. The trade was a 2.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,913 shares of company stock valued at $426,806. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $151.33 on Friday. The firm has a market cap of $41.70 billion, a PE ratio of 38.31, a PEG ratio of 10.59 and a beta of 0.22. The firm has a fifty day moving average of $150.72 and a 200 day moving average of $175.54. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm's revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company's payout ratio is presently 106.33%.

Analysts Set New Price Targets

BDX has been the subject of several recent research reports. Citigroup cut their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a "buy" rating for the company in a report on Tuesday, February 10th. TD Cowen cut their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a "hold" rating for the company in a report on Monday, May 4th. Wells Fargo & Company lifted their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an "equal weight" rating in a report on Friday, May 8th. Evercore lifted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a report on Thursday, May 7th. Finally, Argus cut their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a "buy" rating for the company in a report on Monday, March 23rd. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $183.64.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.